Navigating the Complexities and Optimizing Imaging Strategies in GIST Clinical Trials
Gastrointestinal Stromal Tumors (GIST) pose unique challenges in clinical settings due to their distinct molecular features and behaviors. Imaging plays a pivotal role in evaluating diagnosis and treatment agents in GIST clinical trials. Various imaging techniques are utilized for monitoring GISTs due to diverse imaging findings and unique changes post-treatment, including recurrence patterns that are not typical of other tumors.
GISTs are the most common mesenchymal tumors in the gut. Initially thought to be leiomyosarcomas, specific mutations in the KIT gene led to GIST being recognized as a distinct type of tumor. GISTs used to have a poor prognosis, but the development of imatinib mesylate, a drug that targets KIT, significantly improved patient outcomes. Over the years, new mutations causing GIST have been identified, and various tyrosine kinase inhibitors have been approved for treatment.
In assessing treatment responses in GIST clinical trials, the RECIST criteria focuses on tumor size changes, offering a standardized approach but potentially missing responses that are not reflected in size changes. Modified RECIST (mRECIST) criteria improve upon RECIST by including nodular enhancement, necrosis, and cystic changes, enhancing response evaluation comprehensiveness. The Choi criteria extends evaluation by considering density and contrast enhancement patterns, providing insights into therapy-induced tumor biology alterations, yet challenges related to its correlation to clinical outcome still remain.
While RECIST emphasizes simplicity and standardization, mRECIST and Choi criteria enhance the sensitivity and comprehensiveness of response assessments, albeit with potential trade-offs in terms of standardization and regulatory acceptance. PET adds value to the assessment as metabolically active GIST accumulates 18FDG, and blockage of the KIT receptor results in a rapid suppression of this activity which may take months to become apparent on CT scan. The strategic selection and application of these criteria based on the specific context of clinical trials can significantly impact the accuracy and depth of response evaluations in GIST clinical trials.
As two of our renowned experts, Dr. Ron Korn (CMO) and Dr. Manish Sharma (CSO) at Imaging Endpoints, concur: “In GIST drug development it is critical to balance the exploratory nature of early-phase trials with the regulatory rigor of late-phase trials and, to design clinical trials that connect the two effectively.”
Imaging Endpoint’s experts leverage the evolving landscape of imaging techniques for GISTs to enrich understanding of treatment responses beyond anatomical changes, while collaborating closely with sponsors, investigators, and regulators to optimize trial design. With an industry-leading track record of improving trial outcomes by implementing the right strategy, our team specializes in optimizing imaging charter and assessment criteria for GIST clinical trials.
To connect with our experienced medical and scientific professionals to explore how our tailored imaging solutions can support your GIST clinical trials.
